Surgical vs Transcatheter Aortic Valve Replacement in Patients With a Low Ejection Fraction.

Currently, there is no preference for surgical (SAVR) vs transcatheter (TAVR) aortic valve replacement in patients with low ejection fraction (EF). The present study retrospectively compared the outcomes of SAVR vs TAVR in patients with EF ≤40% (70 SAVR and 117 TAVR patients). Study outcomes were survival and the composite endpoint of stroke, aortic valve reintervention, and heart failure readmission. The patients who had TAVR were older (median: 75 (25-75th percentiles: 69-81) vs 51 (39-66) years old; < .001) with higher EuroSCORE II (4.95 (2.99-9.85) vs 2 (1.5-3.25); < .001). Postoperative renal impairment was more common with SAVR (8 (12.5%) vs 4 (3.42%); = .03), and they had longer hospital stay [9 (7-15) vs 4 (2-8) days; < .001). There was no difference between groups in stroke, reintervention, and readmission (Sub-distributional Hazard ratio: .95 (.37-2.45); = .92). Survival at 1 and 5 years was 95% and 91% with SAVR and 89% and 63% with TAVR. Adjusted survival was comparable between groups. EF improved significantly (β: .28 (.23-.33); < 0.001) with no difference between groups ( = .85). In conclusion, TAVR could be as safe as SAVR in patients with low EF.